# A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19

> **NCT05156645** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Sinocelltech Ltd.**

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** SCTA01 and SCTA01C
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05156645
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01-15
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was withdraw due to the fast spread of Omicron variant worldwide
- **Last updated:** 2022-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05156645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05156645, "A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05156645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*